Ex-Turn­ing Point ex­ecs plan to have their next bet, Aven­zo, on the Nas­daq next sum­mer

The crew at Turn­ing Point Ther­a­peu­tics is back to­geth­er for a new biotech that wants to ac­quire ear­ly-stage on­col­o­gy small mol­e­cules, in­clud­ing an­ti­body drug con­ju­gates …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER